Pune, Nov. 11, 2022 (GLOBE NEWSWIRE) -- “Glоbаl Metformin Hydrochloride Маrkеt” іѕ thе tіtlе оf а rесеntlу рublіѕhеd rероrt bу JCMR market research. Тhе rеѕеаrсh ѕtudу іnvоlvеd ехреrt оріnіоn and with ...

In Phase 3 studies, INVOKANA® plus metformin lowered blood sugar and reduced secondary endpoints of body weight and systolic blood pressure to a greater degree than metformin alone RARITAN, N.J, ...

Whitehouse Station, NJ - Merck announced on February 2, 2012 that the US Food and Drug Administration (FDA) has approved Janumet XR (sitagliptin and extended-release metformin hydrochloride) tablets ...

LINCOLNSHIRE, Ill., November 1, 2005 – Takeda Pharmaceuticals North America, Inc. today announced that ACTOplus met TM (pioglitazone HCl and metformin HCl) is now available by prescription in ...

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY), and AstraZeneca (NYSE: AZN) today announced that KOMBIGLYZE ™ XR (saxagliptin and metformin HCl extended-release), ...

Details concerning the Metformin Hydrochloride (SR) combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ...

One of the manufacturers of a Type 2 diabetes drug, Metformin Hydrochloride Extended-Release Tablets, extended its recall of its 500mg and 750 mg pills, the U.S. Food and Drug Administration reported ...

The Metformin Hydrochloride API Market report is a look of first-hand information, qualitative and quantitative assessment by market analysts, inputs from industry experts and industry participants ...

FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes First and only oral antidiabetic fixed-dose combination medication ...

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved KOMBIGLYZE ™ ...

Metformin, a medication to treat type 2 diabetes, is facing a recall over concerns it has been contaminated with a possible cancer-causing substance. Nostrum Laboratories Inc., the maker of Metformin, ...